TABLE 1.
Baseline clinical characteristics of the intention-to-treat population
| Characteristic | Liraglutide | Glargine | P |
|---|---|---|---|
| Age, years (liraglutide, n = 136; insulin glargine, n = 137) | 56.1 ± 9.5 | 55.9 ± 11.2 | 0.93 |
| Weight, kg (liraglutide, n = 136; insulin glargine, n = 137) | 101.0 ± 20.6 | 98.2 ± 18.0 | 0.24 |
| BMI, kg/m2 (liraglutide, n = 136; insulin glargine, n = 137) | 33.5 ± 5.3 | 33.3 ± 5.3 | 0.79 |
| Sex, n (%) | 0.09 | ||
| Female | 47 (35) | 61 (45) | |
| Male | 89 (65) | 76 (55) | |
| Race, n (%) | 0.83 | ||
| Black | 97 (71) | 95 (69) | |
| White | 23 (17) | 27 (20) | |
| Other | 16 (12) | 15 (11) | |
| Duration of diabetes, years (liraglutide, n = 135; insulin glargine, n = 137) | 9.5 ± 7.8 | 9.8 ± 9.1 | 0.77 |
| Hospital service, n (%) | 0.35 | ||
| Medicine | 116 (85%) | 122 (89%) | |
| Surgery | 20 (15) | 15 (11) | |
| Treatment prior to admission, n (%) | 0.90 | ||
| No diabetes medication | 22 (16) | 24 (18) | |
| Oral agents | 61 (45) | 69 (51) | |
| Insulin | 22 (16) | 19 (14) | |
| Oral agents + insulin | 30 (22) | 23 (17) | |
| Admission HbA1c, % (mmol/mol) | 8.3 ± 0.9 | 8.4 ± 0.8 | 0.41 |
| 67.2 ± −13.6 | 68.3 ± −14.7 | ||
| Admission blood glucose, mmol/L (liraglutide, n = 136; insulin glargine, n = 136) | 11.05 ± 3.7 | 10.77 ± 3.5 | 0.38 |
| Randomization blood glucose, mmol/L (liraglutide, n = 134; insulin glargine, n = 131) | 10.3 ± 3.1 | 10.1 ± 3.0 | 0.68 |
| Median (range) length of stay, days | 4.0 (1.0, 58) | 4.0 (1.0, 33) | 0.35 |
Note: Data are means ± SD, unless otherwise indicated.
Abbreviations: BMI, body mass index; HbA1c, glycated haemoglobin.